The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma.

Kinahan, Cristina; Mangone, Michael A; Scotto, Luigi; Visentin, Michele; Marchi, Enrica; Cho, Hearn Jay; O'Connor, Owen A.

Afiliação

Kinahan C; Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA.
Mangone MA; Co-first authors.
Scotto L; Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA.
Visentin M; Co-first authors.
Marchi E; Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA.
Cho HJ; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
O'Connor OA; Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA.

Oncotarget ; 11(18): 1576-1589, 2020 May 05.

Article em En | MEDLINE | ID: mdl-32405334